Brief: IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
20/08/2024 13:26
Aug 20 (Reuters) - IGC Pharma Inc IGC.A :
* IGC PHARMA: EXPANDS DRUG PORTFOLIO TO METABOLIC DISORDERS
WITH
IGC-1A, POTENTIAL NEW GLP-1 AGONIST
Source text for Eikon: ID:nBw9KqYh1a
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment